Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect

The article announces a first head-to-head preclinical comparison of gut microbiome changes associated with novel oral PolC (pol IIIC*) inhibitors versus linezolid in a murine neutropenic thigh infection model. It also notes structural molecular modifications to molecules related to ibezapolstat, but provides no numerical results or evidence of clinical outcomes.